Whitney Curtis / AP
Researchers are questioning the value, effectiveness and prescribing patterns of H.P. Acthar Gel, a drug used to treat multiple sclerosis and other conditions that costs $38,000 per year, Business Insider reports. Medicare continues to pay more for the drug every year even though experts believe cheaper alternatives would suffice.
Why this matters: It's another knock against Acthar and its owner Mallinckrodt Pharmaceuticals, which has routinely found itself in the spotlight for high drug prices. The New York Times and ProPublica have reported about Acthar's soaring price and taxpayer spending since 2012.